Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20:685–95.

Article  PubMed  Google Scholar 

Brown E, Rajeev SP, Cuthbertson DJ, Wilding JPH. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(Suppl 2):9–18.

Article  CAS  PubMed  Google Scholar 

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

Article  CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

Article  CAS  PubMed  Google Scholar 

Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632–44.

Article  PubMed  PubMed Central  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

Article  CAS  PubMed  Google Scholar 

Zelniker TAWS, Raz I, Im K, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018;393:31–9.

Article  PubMed  Google Scholar 

McMurray JJV, et al. DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.

Article  CAS  PubMed  Google Scholar 

Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:989–91.

Article  Google Scholar 

Perseghin G, Solini A. The EMPA-REG outcome study: critical appraisal and potential clinical implications. Cardiovasc Diabetol. 2016;4(15):85.

Article  Google Scholar 

Gao M, Bhatia K, Kapoor A, Badimon J, Pinney SP, Mancini DM, Santos-Gallego CG, Lala A. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(4): e245135.

Article  PubMed  PubMed Central  Google Scholar 

Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, Levasseur JL, Jahng JWS, Vos D, Parajuli N, El-Kadi AOS, Braam B, Young ME, Verma S, Light PE, Sweeney G, Seubert JM, Dyck JRB. Empagliflozin blunts worsening cardiac dysfunction associated with reduced nlrp3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13(1): e006277.

Article  CAS  PubMed  Google Scholar 

Connelly KA, Zhang Y, Visram A, Advani A, Batchu SN, Desjardins JF, Thai K, Gilbert RE. Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. JACC Basic Transl Sci. 2019;4(1):27–37.

Article  PubMed  PubMed Central  Google Scholar 

Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90–100.

Article  CAS  PubMed  Google Scholar 

Lioudaki E, Androulakis ES, Whyte M, Stylianou KG, Daphnis EK, Ganotakis ES. The effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiometabolic profile; beyond the hypoglycaemic action. Cardiovasc Drugs Ther. 2017;31:215–25.

Article  CAS  PubMed  Google Scholar 

Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17:761–72.

Article  CAS  PubMed  Google Scholar 

Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–17.

Article  CAS  PubMed  Google Scholar 

Angermann CE, Santos-Gallego CG, Requena-Ibanez JA, Sehner S, Zeller T, Gerhardt LMS, Maack C, Sanz J, Frantz S, Fuster V, Ertl G, Badimon JJ. Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure. Nat Cardiovasc Res. 2023;2(11):1032–43.

Article  PubMed  PubMed Central  Google Scholar 

Spigoni V, Fantuzzi F, Carubbi C, Pozzi G, Masselli E, Gobbi G, Solini A, Bonadonna RC, Dei CA. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol. 2020;19(1):46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–7.

Article  CAS  PubMed  Google Scholar 

Heinisch PP, Bello C, Emmert MY, Carrel T, Dreßen M, Hörer J, Winkler B and Luedi MM. Endothelial Progenitor Cells as Biomarkers of Cardiovascular Pathologies: A Narrative Review. Cells. 2022;11.

Ng CY, Cheung C. Origins and functional differences of blood endothelial cells. Semin Cell Dev Biol. 2024;155:23–9.

Article  CAS  PubMed  Google Scholar 

Vega FM, Gautier V, Fernandez-Ponce CM, Extremera MJ, Altelaar AFM, Millan J, Tellez JC, Hernandez-Campos JA, Conejero R, Bolivar J, Pardal R, Garcia-Cózar FJ, Aguado E, Heck AJR, Duran-Ruiz MC. The atheroma plaque secretome stimulates the mobilization of endothelial progenitor cells ex vivo. J Mol Cell Cardiol. 2017;105:12–23.

Article  CAS  PubMed  Google Scholar 

Huang PH, Chen JW, Lin SJ. Effects of cardiovascular risk factors on endothelial progenitor cell. Acta Cardiol Sin. 2014;30:375–81.

PubMed  PubMed Central  Google Scholar 

Benítez-Camacho J, Ballesteros A, Beltrán-Camacho L, Rojas-Torres M, Rosal-Vela A, Jimenez-Palomares M, Sanchez-Gomar I, Durán-Ruiz MC. Endothelial progenitor cells as biomarkers of diabetes-related cardiovascular complications. Stem Cell Res Ther. 2023;14:324.

Article  PubMed  PubMed Central  Google Scholar 

Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600.

Article  PubMed  Google Scholar 

Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999–1007.

Article  CAS  PubMed  Google Scholar 

Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111(22):2981–7.

Article  PubMed  Google Scholar 

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–77.

Article  PubMed  Google Scholar 

Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043–140.

Article  CAS  PubMed  Google Scholar 

Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110:624–37.

Article  CAS  PubMed